Hypertension (HTN) is a common disease, which main manifestation is high blood pressure (BP). Nowadays, HTN is found in 30-40% of the adult population of the world. The prevalence of HTN in the population increases with age. Among people aged 18-29 years old the prevalence of HTN is 4%; aged 50-59 years old – 44%; among people aged 60-69 years old – 54%, and aged 70 and older – 65%. The aim of this study was to evaluate the range and economic affordability of antihypertensive drugs. The analysis has shown that the range of the first line antihypertensive drugs includes 35 INNs of drugs represented by 570 TNs. Most part of the market – 68.5% is taken by foreign drugs and only 31.1% – by domestic drugs. The range of antihypertensive drugs includes drugs of different generations: in addition to well-known drugs there are also new ones that have significant advantages both in terms of clinical efficiency and safety. The analysis of economic affordability has shown that the vast majority of drugs are highly affordable for the Ukrainian consumers, and their total number when calculated at the maximum price is 54.3% (19 INNs) of all drugs presented at the Ukrainian pharmaceutical market. The share of drugs with average affordability is 37.1% (13 INNs); it allows the average citizen of Ukraine taking drugs during the entire treatment of HTN without experiencing a significant impact on his/her own budget, and only 8.6% (3 INNs) are drugs with low affordability. But drugs with low affordability are modern and have significant advantages when used in clinical practice compared to available analogs.

Based on data of the Ministry of Health, when analyzing the HTN structure by the level of BP, 50% of patients had arterial hypertension (AHT) of the 1st level, every third – AHT of the 2nd level, and every fifth – AHT of the 3rd level [7]. Among those with high blood pressure 67.8% of rural and 80.8% of urban residents are aware of the presence of the disease, 38.3% and 48.4% are treated, and the treatment efficiency is 8.1% and 18.7%, respectively. Thus, the situation as to the AHT monitoring is unsatisfactory in both rural and urban population, but it is extremely unfavorable in rural areas [6]. Based on the data from a large-scale meta-analysis it has been confirmed that the first line drugs for treating HTN are diuretics (thiazide and thiazide-like) (the main mechanism of action of thiazide diuretics is the rapid elimination of sodium and potassium ions, thus achieving maximum excretion of liquid from the body that leads to decrease of BP), angiotensin-converting-enzyme inhibitors
Groups of antihypertensive drugs, their International Nonproprietary Names (INNs) and the number of trade names (TNs) presented at the Ukrainian pharmaceutical market

| Group of antihypertensive drugs | INNs and the number of TNs |
|---------------------------------|-----------------------------|
| Beta-blockers (C07A) 8 INNs, 143 TNs | Propranolol (4 TNs), metoprolol (23 TNs H), atenolol (12 TNs), betaxolol (3 TNs), bisoprolol (59 TNs), esmolol (1 TN), nebivolol (10 TNs), carvedilol (3 1 TNS) |
| Angiotensin-converting-enzyme inhibitors (ACE inhibitors) (C09A) 10 INNs, 172 TNs | Captopril (8 TNs), enalapril (41 TNs), lisinopril (60 TNs), perindopril (10 TNs), ramipril (40 TNs), fosinopril (4 TNs), spirapril (1 TN), moexipril (4 TNs), zofenopril (3 TNs), enalaprilat (1 TN) |
| Angiotensin II receptor blockers (AA II) (C09D) 6 INNs, 94 TNs | Losartan (34 TNs), eprosartan (1 TN), valsartan (21 TNs), ibesartan (7 TNs), candesartan (13 TNs), telmisartan (18 TNs) |
| Calcium channel blockers (CCB) (C08C) 9 INNs, 143 TNs | Amlodipine (66 TNs), felodipine (4 TNs), nifedipine (23 TNs), nimodipine (5 TNs), nitrendipine (2 TNs), lercanidipine (10 TNs), lacidipine (2 TNs), verapamil (22 TNs), diltiazem (9 TNs) |
| Thiazide and thiazide-like diuretics (TD) (C03B) 2 INNs, 18 TNs | Hydrochlorothiazide (3 TNs), indapamide (15 TNs) |

The availability of a large number of pharmacological drugs for antihypertensive therapy greatly increases the chance of achieving blood pressure control in vast majority of patients. It is important to take into account the proven fact that the BP decrease only by 5-6 mm Hg is associated with reduced mortality due to cardiovascular diseases by 21%, frequency of strokes by 42% and myocardial infarction by 14% [6, 7].

The data of evidence-based medicine suggest that the rational antihypertensive therapy significantly improves the prognosis of patients with HTN. Therefore, the aim of this study was to evaluate the cost and economic affordability of antihypertensive drugs.

To achieve this goal, it was necessary to solve the following problems:

1. to conduct the analysis of the range of antihypertensive drugs presented at the Ukrainian pharmaceutical market;
2. to assess the economic affordability of the first line antihypertensive drugs for patients.

Materials and Methods

The analysis of the range of domestic and foreign antihypertensive drugs at the pharmaceutical market was conducted based on the data of Morion Pharmstandard Analytical Market Research System [8]. To assess the economic affordability of the antihypertensive therapy the coefficient of the solvency adequacy (Ca.s) showing what percentage of the average wage of the Ukrainian consumer should be spent on the course of treatment with the drug was used. The greater the value of Ca.s is, the less affordable is the drug for the consumer. The coefficient of the solvency adequacy was calculated by the formula:

\[ Ca.s = \frac{P.c.t}{W.a.w.} \times 100\% \]

where: Ca.s – is the coefficient of the solvency adequacy; P.c.t. – is the cost of treatment; W.a.w. – is the average wage within the year under study [10].

The value of the average wage was found on the website:
Results and Discussion

There were 5 groups of first line antihypertensive drugs at the Ukrainian pharmaceutical market (Tab. 1).

The range of antihypertensive drugs has 35 International Nonproprietary Names (INNs) of drugs presented by 570 trade names (TNs). The share of foreign drugs is 68.5%, and domestic drugs – 31.5% (Fig. 1).

The greatest number of TNs of drugs 33.3% is presented in the group of angiotensin-converting-enzyme inhibitors (190 TNs), which leaders are enalapril (41 TNs), lisinopril (60 TNs) and ramipril (40 TNs), the significant share belongs to beta-blockers – 25.1% (143 TNs) and calcium channel blockers (143 TNs) – 25.1%, a slightly lower proportion is taken by angiotensin II receptor blockers – 13.3%, and the lowest share of 3.3% is taken by the group of thiazide diuretics (18 TNs) (Fig. 2).

The next stage of this study was to assess economic affordability of antihypertensive drugs belonging to the standard of medical care of patients with HTN and those present at the Ukrainian pharmaceutical market (Tab. 2).

Based on the data obtained it has been found that all antihypertensive drugs are highly affordable (Ca.s < 5%), except for Felodip and Enap®, by the Ca.s value at the minimum price per the course of treatment (30 days). The coefficient of the solvency adequacy of the most drugs provides availability of the drug and guarantees the sale against the low paying capacity of the population. Felodip belongs to blockers of “slow” calcium channels of dihydropyridines. It reduces the size of myocardial infarction and protects against reperfusion complications. It practically has no negative effects with the minimal effect on the cardiac conduction system. Enap® inhibits angiotensin-converting enzyme, reduces the concentration of angiotensin II and aldosterone in the blood and improves the kallikrein-kinin vasodepressor system functioning. The drug reduces TPR, SBP and DBP. The action begins in 1.5-15 min after intravenous injection, reaches the maximum in 1-4 hours and lasts about 6 hours. These drugs have average affordability, their Ca.s = 5.02% and 7.88%, respectively. These drugs are less affordable, but taking into account the peculiarities of their pharmacological profile they can be used widely in Ukraine.

The Ca.s values calculated by the maximum price show that drugs by 13 INNs are with average affordability (Ca.s < 15%) and by 3 INNs – with low affordability (Cas > 15%). The drugs with low affordability include: Diovan (valsartan) (film-coated tablets, 80 mg, No.28 Novartis Pharma (Switzerland); it has a selective antagonistic action with respect to the receptor apparatus of angiotensin II (AT II). Diovan has no active metabolite and does not require biotransformation during the initial passage through the liver. It has high (95%) ability to bind to plasma proteins, primarily albumin. The effect of the dose lasts for up to 24 hours, it increases compliance of patients to therapy. The efficiency does not depend on sex, age and race. Valsartan is not inferior to amlodipine, hydrochlorothiazide and lisinopril by its antihypertensive efficiency and even exceeds the latter by tolerability. The probability of cough when using valsartan is very low due to the lack of impact on ACE, which is responsible for degradation of bradykinin. Comparison of Diovan with ACE inhibitor showed that the incidence of dry cough was significantly lower in patients receiving Diovan than in patients treated with ACE inhibitor (2.6 vs. 7.9%, respectively). The use of this drug is not accompanied by a sharp decrease in blood pressure, or other adverse clinical consequences.
Another drug with low affordability presented at our market is Lisinovel (tabl., 10 mg, in blister, No.10, Astrapharm (Ukraine) – ACE inhibitor. Inhibition of the ACE activity leads to reduction of angiotensin II in the blood plasma, decrease in aldosterone release and, as a consequence, lowering of blood pressure in patients with hypertension, and improves the course of heart failure. In patients with essential hypertension decrease of blood pressure is associated with decrease in total peripheral resistance with little change in the heart rate. The hypotensive effect develops in almost an

| INN      | min cost of a package (UAH) | Ca.s min per the course of treatment (30 days) | max cost of a package (UAH) | Ca.s max per the course of treatment (30 days) |
|----------|-----------------------------|-----------------------------------------------|----------------------------|-----------------------------------------------|
| **Beta-blockers (C07A)** |                             |                                               |                            |                                               |
| Propranolol | 42.59                       | 1.35                                          | 76.11                      | 2.42                                          |
| Metoprolol | 8.71                        | 0.28                                          | 197.38                     | 6.27                                          |
| Atenolol   | 6.04                        | 0.19                                          | 59.16                      | 1.88                                          |
| Betaxolol  | 76.33                       | 2.42                                          | 183.85                     | 4.19                                          |
| Bisoprolol | 9.61                        | 0.31                                          | 104.4                      | 3.3                                           |
| Esmolol    | 2,591.32                    | –                                             | 2,591.32                   | 82.27                                         |
| Nebivolol  | 47.28                       | 1.5                                           | 126.92                     | 4.03                                          |
| Carvedilol | 24.19                       | 0.77                                          | 453.29                     | 14.39                                         |
| **Angiotensin-converting-enzyme inhibitors (C09A)** |                             |                                               |                            |                                               |
| Captopril | 21.56                       | 0.68                                          | 124.15                     | 3.94                                          |
| Enalapril  | 5.53                        | 0.18                                          | 156.12                     | 4.96                                          |
| Lisinopril | 6.41                        | 0.2                                           | 498.03                     | 15.81                                         |
| Perindopril| 39.66                       | 1.26                                          | 102.75                     | 3.26                                          |
| Ramipril   | 27.38                       | 0.87                                          | 190.75                     | 6.06                                          |
| Fosinopril | 82.07                       | 2.61                                          | 196.28                     | 6.23                                          |
| Spirapril  | 115.07                      | –                                             | 115.07                     | 3.65                                          |
| Moexipril  | 77.03                       | 2.45                                          | 230.13                     | 7.31                                          |
| Zofenopril | 137.4                       | 4.36                                          | 178.29                     | 4.66                                          |
| Enalaprilat| 248.2                       | –                                             | 248.2                      | 7.88                                          |
| **Angiotensin II receptor blockers (C09D)** |                             |                                               |                            |                                               |
| Losartan   | 16.11                       | 0.51                                          | 261.65                     | 8.31                                          |
| Eprosartan | 122.97                      | –                                             | 122.97                     | 3.9                                           |
| Valsartan  | 58.71                       | 1.86                                          | 1,126.49                   | 35.76                                         |
| Ibesartan  | 57.14                       | 1.81                                          | 151.39                     | 4.81                                          |
| Candesartan| 26.37                       | 0.84                                          | 254.59                     | 8.08                                          |
| Telmisartan| 39.23                       | 1.25                                          | 196.31                     | 6.23                                          |
| **Calcium channel blockers (C08C)** |                             |                                               |                            |                                               |
| Amlodipine | 8.96                        | 0.28                                          | 206.12                     | 6.54                                          |
| Felodipine | 158.24                      | 5.02                                          | 309.57                     | 9.83                                          |
| Nifedipine | 3.97                        | 0.13                                          | 461.81                     | 14.66                                         |
| Nimodipine | 71.22                       | 2.26                                          | 88.14                      | 2.80                                          |
| Nitrendipine| 112.43                      | 3.57                                          | 153.95                     | 4.89                                          |
| Lacidipine | 130.58                      | 4.15                                          | 140.13                     | 4.45                                          |
| Lercanidipine| 37.85                      | 1.20                                          | 95.30                      | 3.03                                          |
| Verapamil  | 3.95                        | 0.13                                          | 351.92                     | 11.17                                         |
| Diltiazem  | 32.39                       | 1.03                                          | 139.61                     | 4.43                                          |
| **Thiazide and thiazide-like diuretics (C03B)** |                             |                                               |                            |                                               |
| Hydrochlorothiazide | 27.52                      | 0.87                                          | 115.5                      | 3.67                                          |
| Indapamide | 16.26                       | 0.52                                          | 91.42                      | 2.9                                           |
hour after administration and reaches its maximum about 6 hours later. The effect lasts for 24 hours and depends on the dose that increases compliance of the patient. The third drug included in the group of drugs with low affordability is Brevibloc (solution for injections, 10 mg/ml, 10 ml vial, No.5, Baxter AG (Switzerland) – it blocks β1-adrenergic receptors, but unlike other drugs of this group Brevibloc differs in ultra-short duration of action (the absolute therapeutic effect develops within 2 min and terminates in 15-20 min after completing the infusion. T 1/2 – 9 min), it provides the successful use in acute situations in case of hypertensive crisis, severe arrhythmias and heart surgery. This drug is almost unavailable for the Ukrainian consumers as Ca.s for it is 82.27 %.

According to the data calculated at the maximum price for the drug and the Ca.s value per the course of treatment of 30 days it has been found that 54.3 % (19 INNs) of antihypertensive drugs at the Ukrainian pharmaceutical market are taken by highly affordable drugs, 37.1 % (13 INNs) – drugs with average affordability and only 8.6 % (3 INNs) – drugs with low affordability for the Ukrainian consumers (Fig. 3). But drugs with low affordability are modern and have significant advantages when used in clinical practice compared to available analogs.

CONCLUSIONS

1. The analysis has shown that the range of the first line antihypertensive drugs includes 35 INNs of drugs represented by 570 TNs. Most part of the market – 68.5 % is taken by foreign drugs and only 31.1 % – by domestic drugs. The range of antihypertensive drugs includes drugs of different generations: in addition to well-known drugs there are also new ones that have significant advantages both in terms of clinical efficiency and safety.

2. The analysis of economic affordability of the first line antihypertensive drugs at the maximum price has shown that the vast majority of drugs are highly affordable for the Ukrainian consumers, and their total number when calculated at the maximum price is 54.3 % (19 INNs) of all drugs presented at the Ukrainian pharmaceutical market. The share of drugs with average affordability is 37.1 % (13 INNs); it allows the average citizen of Ukraine taking drugs during the entire treatment of HTN without experiencing a significant impact on his/her own budget, and only 8.6 % (3 INNs) are drugs with low affordability. But drugs with low affordability are modern and have significant advantages when used in clinical practice compared to available analogs.

REFERENCES

1. Голяченко О.М., Голяченко А.О. // Вісник наукових досліджень (Тернопільська державна медична академія ім. І.Я.Горбачевського). – 2011. – №4. – С. 38-41.
2. Горбась І.М., Смирнова І.П., Кваша О.О., Дорогой А.П. // Артериальна гіпертензія. – 2010. – №6 (14). – С. 51-82.
3. Коваленко В.М., Корнацький В.М. Медико-соціальні аспекти хвороб системи кровообігу: Аналітично-статистичний посібник. – К., 2010. – 144 с.
4. Коваленко В.М., Корнацький В.М. Динаміка стану здоров’я народу України та регіональні особливості: Аналітично-статистичний посібник. – К., 2012. – 211 с.
5. Коваленко В.М., Корнацький В.М. Регіональні медико-соціальні проблеми хвороб системи кровообігу: Аналітично-статистичний посібник. – К., 2013. – 239 с.
6. Коваленко Н.В. Керівництво по кардіології. – К.: Морион, 2008. – 460 с.
7. Наказ МОЗ України від 24.05.2012 р. №384 «Про затвердження та впровадження медико-тезноло-гічних документів зі стандартизації медичної допомоги при артеріальній гіпертензії».
8. Програмний комплекс «Аптека» компанії «Моріон» [Електронний ресурс] – Режим доступу до сайту: http://pharmbase.com.ua/poisk/.
9. Тиск у нормі – запорука здоров’я // Медичний світ. – 2014. – Електронний ресурс. – Доступ до статті: http://medsvit.org/articles/1/396/tisk-u-norm-zaporuka-zdorov-ya/?print=1
10. Яковлєва Л.В., Бондаренко Д.В. // Укр. біофармац. журн. – 2015. – №2 (37). – С. 4-10.
АНАЛІЗ ЕКОНОМІЧНОЇ ДОСТУПНОСТІ АНТИГІПЕРТЕНЗИВНОЇ ТЕРАПІЇ ГІПЕРТОНІЧНОЇ ХВОРОБИ
Л.В.Яковлєва, О.С.Цвик
Національний фармацевтичний університет

Ключові слова: гіпертонічна хвороба; коефіцієнт доступності; показник адекватності платоспроможності; антигіпертензивні препарати першої лінії застосування

Гіпертонічна хвороба (ГХ) – розповсюджена захворювання, основним проявом якого є підвищення артеріального тиску (АТ). На теперішній час ГХ виявлена у 30-40% дорослого населення країн світу. Появлення ГХ в популяції з віком збільшується. Серед осіб 18-29 років поширеність ГХ становить 4%; у віці 50-59 років – 44%; серед осіб 60-69 років – 54%, а у віці 70 років і старше – 65%. Метою даної роботи була оцінка асортименту та економічної доступності антигіпертензивних препаратів. У результаті проведеного аналізу було встановлено, що асортимент антигіпертензивних ЛЗ першої лінії застосування налічує 35 МНН препаратів, які представлені 570 ТН. Більшу частину ринку – 68,5% складають ЛЗ зарубежного виробництва і лише 31,1% – вітчизняні ЛЗ. Асортимент антигіпертензивних ЛЗ включає препарати різних поколінь: поряд із широко відомими є нові препарати, що мають суттєві переваги як за клінічною ефективністю, так і за безпечністю. Аналіз економічної доступності показав, що переважна більшість препаратів є високодоступними для українського споживача, їх загальна кількість при розрахунку за максимальною ціною складає 54,3% (19 МНН) від усіх представленних ЛЗ на фармацевтичному ринку України. Частка середнедоступних препаратів складає 37,1% (13 МНН), що дає змогу середньостатистичному жителю України приймати ЛЗ протягом усього курсу лікування ГХ, не відчувати значного впливу на власний бюджет, і лише 8,6% (3 МНН) є малодоступними ЛЗ. Але малодоступні ЛЗ є сучасними і мають суттєві переваги при застосуванні в клінічній практиці у порівнянні з доступними аналогами.

Адреса для відповіді:
4, Valentynivska str., Kharkiv, 61168, Ukraine.
Tel. (572) 65-88-95. E-mail: leknfau@ukr.net.
National University of Pharmacy